XML 38 R27.htm IDEA: XBRL DOCUMENT

OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2022

Fair Value Measurements, Recurring and Nonrecurring

The fair values of our financial instruments at June 30, 2022 and December 31, 2021 were (in thousands):


	Total		Level 1		Level 2		Level 3
2022
Financial Assets
Convertible note receivable embedded derivative	$	355	$	—	$	—	$	355
Promissory note receivable derivative	337		—		—		337
Financial Liabilities
BiEsseA contingent consideration	1,777		—		—		1,777
Notes payable	15,900		—		—		15,900
Balances, June 30, 2022	$	18,369	$	—	$	—	$	18,369

2021	Total		Level 1		Level 2		Level 3

Financial Assets
Convertible note receivable embedded derivative	$	888	$	—	$	—	$	888
Promissory note receivable embedded derivative	337		—		—		337
Financial Liabilities
BiEsseA contingent consideration	2,334		—		—		2,334
Notes payable	15,900		—		—		15,900
Balances, December 31, 2021	$	19,459	$	—	$	—	$	19,459

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table presents the changes of our Level 3 assets and liabilities as of June 30, 2022 (in thousands):


	Derivative Assets				Contingent Consideration Liability		Notes Payable
	Convertible note receivable		Promissory note receivable		BSA		Biotech
Balances, December 31, 2021	$	888	$	337	$	2,334	$	15,900
Acquisition value	—		—		—		—
Cash payments	—		—		—		—
Changes in fair value	(533)		—		(294)		—
Foreign currency impact	—		—		(263)		—
Balances, June 30, 2022	$	355	$	337	$	1,777	$	15,900

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

The following table presents the changes of our Level 3 assets and liabilities as of June 30, 2022 (in thousands):


	Derivative Assets				Contingent Consideration Liability		Notes Payable
	Convertible note receivable		Promissory note receivable		BSA		Biotech
Balances, December 31, 2021	$	888	$	337	$	2,334	$	15,900
Acquisition value	—		—		—		—
Cash payments	—		—		—		—
Changes in fair value	(533)		—		(294)		—
Foreign currency impact	—		—		(263)		—
Balances, June 30, 2022	$	355	$	337	$	1,777	$	15,900

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details